ArticleVeterinary research communications2004
A pharmacokinetic comparison of meloxicam and ketoprofen following oral administration to healthy dogs.
Article in Veterinary research communications, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- Pharmacokinetics of Single-dose Subcutaneous Meloxicam Injections in Black-tailed Prairie Dogs (Journal of the American Association for Laboratory Animal Science : JAALAS · 2017Trial
- Bioavailability and pharmacokinetics of oral meloxicam in llamas.BMC veterinary research · 2012Trial
- Evaluating Orally Administered Meloxicam-Loaded Polymeric Nanocapsules in Female Dogs: A Population Pharmacokinetic Modeling Study.Pharmaceuticals (Basel, Switzerland) · 2026Article
- Pharmacokinetics of Meloxicam in Different Animal Species: A Comprehensive Review.Veterinary sciences · 2024Review
- Measurement of Cyclooxygenase Products in Plasma as Markers for Inhibition of Cyclooxygenase Isoforms by Oral Meloxicam in New Zealand White Rabbits (Journal of the American Association for Laboratory Animal Science : JAALAS · 2023Article
- Challenges with Assessing and Treating Pain in Research Primates: A Focused Survey and Literature Review.Animals : an open access journal from MDPI · 2022Review
- Pharmacokinetics of the Anti-Inflammatory Drug Meloxicam after Single 1.5 mg/kg Intramuscular Administration to Undulate Skates (Veterinary sciences · 2022Article
- Pharmacokinetic Evaluation of a Novel Transdermal Ketoprofen Formulation in Healthy Dogs.Pharmaceutics · 2022Article
- Pharmacokinetic Studies in Elasmobranchs: Meloxicam Administered at 0.5 mg/kg Using Intravenous, Intramuscular, and Oral Routes to Nusehound Sharks (Frontiers in veterinary science · 2022Article
- Multi-Injection Pharmacokinetics of Meloxicam in Kemp's RidleyAnimals : an open access journal from MDPI · 2021Article
- Plasma pharmacokinetic profile and efficacy of meloxicam administered subcutaneously and intramuscularly to sheep.PloS one · 2019Article
- Development of Tizanidine HCl-Meloxicam loaded mucoadhesive buccal films: In-vitro and in-vivo evaluation.PloS one · 2018Article
- Meloxicam decreases the migration and invasion of CF41.Mg canine mammary carcinoma cells.Oncology letters · 2017Article
- Pharmacokinetics of 3 formulations of meloxicam in cynomolgus macaques (Macaca fascicularis).Journal of the American Association for Laboratory Animal Science : JAALAS · 2014Article
- Aqueous stability and oral pharmacokinetics of meloxicam and carprofen in male C57BL/6 mice.Journal of the American Association for Laboratory Animal Science : JAALAS · 2013Article
- Removing the threat of diclofenac to critically endangered Asian vultures.PLoS biology · 2006Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ketoprofen (KTP) and meloxicam (MLX) are non-steroidal anti-inflamatory drugs used extensively in veterinary medicine. The pharmacokinetics of these drugs were studied in eight dogs following a single oral dose of 1 mg/kg of KTP as a racemate or 0.2 mg/kg of MLX. The concentrations of the drugs in plasma were determined by high-performance liquid chromatography (HPLC). There were differences between the disposition curves of the KTP enantiomers, confirming that the pharmacokinetics of KTP is enantioselective. (S)-(+)-KTP was the predominant enantiomer; the S:R ratio in the plasma increased from 2.58 +/- 0.38 at 15 min to 5.72 +/- 2.35 at 1 h. The area under the concentration time curve (AUC) of (S)-(+)-KTP was approximately 6 times greater than that of (R)-(-)-KTP. The mean (+/- SD) pharmacokinetic parameters for (S)-(+)-KTP were characterized as Tmax = 0.76 +/- 0.19 h, Cmax = 2.02 +/- 0.41 microg/ml, t1/2el = 1.65 +/- 0.48 h, AUC = 6.06 +/- 1.16 microg.h/ml, Vd/F = 0.39 +/- 0.07 L/kg, Cl/F = 170 +/- 39 ml/(kg.h). The mean (+/- SD) pharmacokinetic parameters of MLX were Tmax = 8.5 +/- 1.91 h, Cmax = 0.82 +/- 0.29 microg/ml, t1/2lambda(z) = 12.13 +/- 2.15 h, AUCinf = 15.41 +/- 1.24 microg.h/ml, Vd/F = 0.23 +/- 0.03 L/ kg, and Cl/F = 10 +/- 1.4 ml/(kg.h). Our results indicate significant pharmacokinetic differences between MLX and KTP after therapeutic doses.
Indexed as
Identifiers
15379436What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.